How to Read an FDA Safety Alert About a GLP-1 (Real Examples)

To read an FDA safety alert about a GLP-1 product, open the original page on fda.gov and find five things: the date (and any update dates), exactly which product or practice it covers, what FDA knows versus is still investigating, what patients are told to do, and how to report problems. Most alerts are narrower than the screenshot that went viral, and the page itself tells you whether it applies to you.

Below, we walk through that method using three real GLP-1 alerts, each a different type. By the end you will be able to read the next one in about five minutes.

What kinds of FDA safety alerts exist for GLP-1 medicines?

Type	What it usually is	Real GLP-1 example
Drug Safety Communication	FDA's update on a safety issue with an approved drug, often tied to a label change	January 2026: FDA requests removal of the suicidal behavior and ideation warning from Saxenda, Wegovy and Zepbound labels
Drug alert or statement	Warnings about counterfeits, unapproved products or other urgent issues	Counterfeit Ozempic in the U.S. supply chain (2023, updated 2025)
Compounding alert	Problems with compounded (not FDA-approved) versions	2024 alert on dosing errors with compounded semaglutide
Shortage, discontinuation or recall notice	Supply status or product removal	See shortage vs discontinuation vs recall

The 5-step method

1. Date and updates. When was it posted, and has it been updated?
2. Scope. Which product, strength, form, lot number, seller or practice?
3. Known vs unknown. What has FDA confirmed, and what is it still investigating?
4. Action. What does it tell patients and clinicians to do?
5. Reporting. How do you report a problem?

Let's practice.

Example 1: Counterfeit Ozempic (scope is everything)

FDA's counterfeit Ozempic page is a great lesson because it has been updated twice. The first alert was posted December 21, 2023, about counterfeit Ozempic 1 mg pens with lot number NAR0074 and serial number 430834149057. FDA added an update on April 14, 2025 (lot PAR0362, serial numbers beginning 51746517), and another on December 5, 2025 (lot PAR1229).

Here is the twist in that last update: PAR1229 is also a genuine lot number. FDA explained how to tell them apart by where the "EXP/LOT" text sits on the pen label (to the left of the expiration date and lot number on counterfeits; above them on authentic pens). It also said patients who received PAR1229 through Novo Nordisk's Patient Assistance Program could keep using it, because that supply was authentic.

Imagine reading only a viral post that says "FDA: lot PAR1229 is fake!" You might throw away genuine medicine. The full page says something much more precise.

Known vs unknown: FDA said it did not know the identity, quality or safety of the seized products and that testing was ongoing. For the 2023 counterfeits, it noted the needles could not be confirmed sterile, which raises infection risk.

Action: check your pens, do not use ones matching the description, get Ozempic only with a prescription from a state-licensed pharmacy, report problems to MedWatch, and call Novo Nordisk at 1-800-727-6500 with questions. Our guide to counterfeit GLP-1 offers online covers how fakes reach people.

Example 2: Compounded semaglutide dosing errors (it is about a practice, not a molecule)

In July 2024 FDA alerted health care providers, compounders and patients to overdoses linked to compounded injectable semaglutide. Some patients drew 5 to 20 times the intended dose from multiple-dose vials, for example taking 50 units on a U-100 syringe instead of 5 units (0.05 mL). Some providers also miscalculated conversions between milligrams, units and milliliters. Reported effects included nausea, vomiting, fainting, dehydration, pancreatitis and gallstones, and some people needed hospital care.

Scope check: this alert concerns compounded products, measured with syringes from vials. It is not about prefilled Wegovy or Ozempic pens. That distinction disappears in a lot of reposts. (Why the units confusion is so dangerous: mg, mL and "units".)

Action: talk with your prescriber or compounding pharmacy about exactly how to measure your dose, and report errors to MedWatch. If you think you took too much, call Poison Control at 1-800-222-1222 or 911 for severe symptoms.

Example 3: The 2026 label change (an alert that reduces a warning)

Not every safety communication adds a warning. On January 13, 2026, FDA asked makers of Saxenda, Wegovy and Zepbound to remove the suicidal behavior and ideation warning. The page follows FDA's standard structure, which is worth learning because you will see it again:

• What Is FDA Doing?
• What Should Patients and Caregivers Do?
• What Should Health Care Professionals Do?
• What Did FDA Find?
• How Do I Report Side Effects?

Known: a meta-analysis of 91 placebo-controlled trials (107,910 participants) and a health-record study of more than 2.2 million people found no increased risk.

Action for patients: keep taking medicine as prescribed, discuss concerns with a clinician, and report new or worsening depression or mood changes. Support is available 24/7 by calling or texting 988.

Lesson: the same five steps work whether an alert adds, narrows or removes a warning.

How to tell whether an alert applies to you

Ask four questions with your box or pen in hand:

• Is it my product? Brand, strength, injection vs tablet, approved vs compounded.
• Is it my lot? The lot number is printed on the carton and pen label.
• Is it my source? Pharmacy, patient assistance program, telehealth seller, or an online offer.
• Is it my timeframe? When did you fill it?

If you keep your pharmacy details and fill dates in a notes app or in a tracker like GLPily, checking this takes seconds instead of a cabinet search. If you are still unsure, call the pharmacy that filled it or the manufacturer number on the alert. Do not stop a prescribed medicine on your own based on a headline; ask your prescriber or pharmacist first.

How to get FDA alerts straight from the source

The January 2026 page includes a section titled "How Can I Get New Safety Information on Medicines I'm Prescribing or Taking?", and that section is the place to start. Getting updates directly from FDA means you see the original instead of someone's summary of it. And if you experience a problem yourself, here is how to report a GLP-1 side effect to MedWatch.

Common questions

Where are FDA safety alerts about GLP-1 drugs posted?

On fda.gov, mainly in the Drug Safety Communications and Drug Alerts and Statements sections, and in compounding alerts for compounded products.

How do I find the lot number on my GLP-1 pen?

It is printed on the carton and on the pen label, usually next to the expiration date, labeled LOT.

Should I stop my medicine if I see an FDA alert?

Not based on a headline alone. Read the "What should patients do?" section, then call your pharmacist or prescriber.

What if my pen matches a counterfeit alert?

Do not use it. Keep it, contact the pharmacy and manufacturer, and report it to FDA MedWatch.